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Background:  Current  recommendations  are that HIV-infected  persons  should  not  be  given  live  vaccines.
We  set  out  to  assess  potential  toxicity  of  three  live,  attenuated  oral  vaccines  (against  rotavirus,  typhoid
and  ETEC)  in  a  phase  1 study.
Methods: Two  commercially  available  oral  vaccines  against  rotavirus  (Rotarix)  and  typhoid  (Vivotif)  and
one  candidate  vaccine  against  Enterotoxigenic  Escherichia  coli (ACAM2017)  were  given  to  HIV seropositive
(n  =  42)  and  HIV  seronegative  (n  =  59)  adults.  Gastrointestinal  symptoms  were  sought  actively  by weekly
interview  up  to 1 month  of vaccination.  In rotavirus  vaccine  recipients,  intestinal  biopsies  were  collected
by  endoscopy  and  evaluated  for expression  of IL-8 and  pro-inﬂammatory  cytokines.
Results: No  difference  was  observed  between  symptoms  in  HIV  infected  and  HIV  uninfected  vaccinees,
except  for diarrhoea  reported  more  than  7  days  after  the  last  dose  of  vaccine.  If only  diarrhoea  episodes
within  7 days  of  vaccination  are  included,  diarrhoea  was  not  more  frequent  in HIV seropositive  than
in  HIV  seronegative  vaccinees  (OR  6.7,  95%  CI 1.2–67;  P  =  0.09).  However,  if  later episodes  of  diarrhoea
are  included,  a  signiﬁcant  increase  in  diarrhoea  was  demonstrated  (OR  5.3,  95%  CI 0.98–53;  P  =  0.04).
All  episodes  were  mild  and  transient.  IL-8  was  slowly  up-regulated  over  the  week  following  vaccination
(P  =  0.02),  but  IL-,  IFN  or TNF  were  not.
Conclusions: No  evidence  was  found  of  adverse  events  following  administration  of  these  three  vaccines,
except  for  late  episodes  of  diarrhoea  which  may  not  be  attributable  to  vaccination.  Our  data  do  not
support  the  need  for  a prohibition  on oral  administration  of live,  attenuated  vaccines  to all  HIV  infected
adults,  though  further  work  on  severely  immunocompromised  adults  and  children  are  required.. Introduction
Diarrhoeal disease remains one of the commonest causes of
eath in children, especially in the malnourished. Up to 2 million
hildren die of diarrhoea each year, and diarrhoea has effects on
ong-term development and growth [1,2]. In Zambia, the preva-
ence of diarrhoea in children under 5 years of age is very high,
ith 21.2% of mothers reporting diarrhoea in a 2-week period [3].
iarrhoea in children is mostly attributed to rotavirus and Entero-
oxigenic Escherichia coli (ETEC). The prospects for global provision
f adequate quantities of clean water are as distant as ever, with
robably over 1 billion people unable to access safe drinking water.
accines against rotavirus, cholera and typhoid are available, but
∗ Corresponding author at: Blizard Institute of Cell and Molecular Science, Barts
 The London School of Medicine and Dentistry, Queen Mary University of London,
urner Street, London E1 2AD, UK. Tel.: +44 20 7882 7191; fax: +44 20 7882 7192.
E-mail address: m.p.kelly@qmul.ac.uk (P. Kelly).
264-410X     © 2012 Elsevier Ltd.  
ttp://dx.doi.org/10.1016/j.vaccine.2012.06.079
Open access under CC BY license.© 2012 Elsevier Ltd. 
some are live, attenuated vaccines which would need to be used
in populations with high HIV prevalence. It would also be desir-
able to offer protection against diarrhoea-causing pathogens to HIV
infected adults and children, so it is imperative to determine if these
vaccines are safe in HIV infected individuals.
Recent highly authoritative guidelines [4] on prevention of
opportunistic infection in HIV-infected children recognise the
potential risk of giving live, inactivated vaccines to potentially
immunocompromised children but make it clear that few data
are available on the magnitude of that risk. A recent analysis of
rotavirus in relation to HIV, and the experience of a trial in South
Africa in which HIV infected children were given a rotavirus vac-
cine, do suggest that it is safe [5]. The oral live, attenuated cholera
vaccine CVD103HgR was found to be safe in HIV-infected adults
in Mali [6], and there is evidence that oral polio vaccine is safe in
Open access under CC BY license.HIV infected children [7]. However, uncertainty remains due to the
paucity of data in African populations [8,9].
In order to address these concerns we  analysed our experi-
ence of giving any of three live, attenuated vaccines to Zambian
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Table 1
Primers used for quantitative PCR for intestinal cytokine expression.
Forward (5′ to 3′) Reverse (3′ to 5′)
IL-1 CGGCCACATTTGCTAAGA AGGGAAGCGGTTGCTCATC
TNF CCCAGGCAGTCAGATCATCTTC GCTTGAGGGTTTGCTACAACATG
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IL-8 TGTGTGTAAACATGACTTCCAAGCT 
GAPDH CCAGCCGAGCCACATCGCTC 
dults. Both the bacterial vaccines are known to be sensitive to
iproﬂoxacin and so we were conﬁdent that this evaluation was
afe in the carefully monitored setting in which they were given.
n the event, none of the recipients needed any medical support
r antibiotic treatment. As rotavirus vaccination programmes are
olled out across sub-Saharan Africa, it is important to assess the
otential toxicity of this vaccine in HIV infection, so a subset of
articipants receiving the rotavirus vaccine underwent intestinal
iopsy to evaluate expression of IL-8, IL-, IFN and TNF.
.  Methods
.1. Participants
The study was conducted in Lusaka, Zambia, between February
008 and October 2009. Participants were drawn from the Misisi
ohort, a mixed cohort of HIV seropositive and seronegative adults,
hich is deﬁned only by residence in a deﬁned area [10]. Poten-
ial participants were not given vaccines if they were pregnant or
actating, had experienced diarrhoea within 1 month before their
lanned participation, had taken antibiotics or non-steroidal anti-
nﬂammatory drugs in the same period, had been vaccinated with
ny other vaccine within 6 months, or were found to have infec-
ion with an intestinal helminth by examination of 3 stool samples
aken over a 3–5-day period. Ethical approval was  obtained from
he University of Zambia Research Ethics Committee (007-10-07)
nd all participants gave written informed consent.
.2. Vaccine administration
Rotarix  (Glaxo Smith Kline, Brentford, UK) is derived from a
uman rotavirus which was attenuated by repeated passage and
s safe in children [11]. The second vaccine, ACAM2017 (Acambis
lc, Cambridge, UK), was derived from a spontaneous LT-negative
TEC isolate which has deletions of the chorismate synthase gene
roC, the membrane proteins ompC and ompF, and the toxin genes
or LT, ST and EAST. The gene for CS1 [12] has been added and it
nduces speciﬁc mucosal IgA against coli surface (CS) antigens CS1,
S2 and CS3 [13]. The third vaccine, Vivotif (Ty21a vaccine; Berna
iotech, Bern, Switzerland), is the only licensed oral typhoid vac-
ine [14]. The gene galE is inactivated and it is unable to express
he pathogenicity factor Vi; it has an excellent safety record. Vivo-
if is immunogenic in the host but has low environmental survival.
ivotif induces anti-LPS systemic IgG and IgA, antibody secreting
ells in peripheral blood, and cell mediated immunity (CMI). Immu-
ity conferred by Ty21a lasts up to 7 years but uniquely requires
–4 doses given only 1–2 days apart [15]. Rotarix was  adminis-
ered as a single dose in 1.3 ml  liquid carbonate buffer according
o the manufacturer’s instructions. ACAM2017 was administered
s a suspension of bacteria prepared by Acambis plc as previously
escribed [13]. The dose of viable organisms in the vaccine vials
3 ×1010) was  conﬁrmed in the laboratory in three test vials which
ere discarded in order to avoid contamination of the vials used
or vaccination. The dose contained in each vial was  administered
s one dose and the vial was then discarded. Vivotif was  adminis-
ered as a capsule, initially as a single dose in 23 participants, thenATCTGACTCCTTTTTCGCTTCC
GCAAAACTGCACCTTCACACAG
ATGAGCCCCAGCCTTCTCCAT
2  doses (on days 1 and 3) in 5 participants, then 3 doses (the full
dosing schedule on days 1, 3, and 5) in a further 5 participants, then
the full schedule for the remainder of the study when safety and
acceptability concerns had been allayed. Altogether, 81 participants
received Vivotif.
2.3.  Adverse event recording
Each  participant was interviewed at 7, 14, 21 and 28 days after
vaccine administration. Direct questions were asked about the
experience of the symptoms listed in Table 2. Full blood count data
collected prior to vaccine administration and either 7 or 14 days
afterwards were also compared.
2.4.  Intestinal cytokine expression
Jejunal  biopsies were collected endoscopically using an Olym-
pus SIF-10 endoscope under diazepam sedation as previously
described [16–18]. Biopsies were obtained 1 day prior to vaccine
administration and at 1 (n = 4), 2 (n = 6), 4 (n = 6), or 7 (n = 5) days
after the ﬁrst vaccine dose. Each participant underwent two endo-
scopies and these biopsies were evaluated as a before/after pair.
Biopsies were collected into 200 l Tri Reagent (Sigma, Poole, UK)
and snap-frozen in liquid nitrogen followed by storage at −80 ◦C.
Biopsies were used within 3 months, and RNA isolated as previously
described [18]. Following reverse transcription, real time quantita-
tive polymerase chain reaction (RT-qPCR) was carried out using
SYBR Green enzyme buffer (Qiagen) with primers shown in Table 1
for the following cytokines: interleukin (IL)-8, IL-1, interferon
(IFN)-, and tumour necrosis factor (TNF)-.
2.5. Data analysis
Diarrhoea or other AEs attributable to vaccine were considered
if the onset was  within 7 days of the last dose of vaccine. All AEs
were compared in HIV seropositive versus HIV seronegative partic-
ipants and proportions analysed using Fisher’s exact test. Cytokine
mRNA measurements were normalised to GAPDH and expressed
as -fold change from baseline to post-vaccination sample, and sta-
tistical signiﬁcance evaluated using the Wilcoxon signed-rank test
to determine if there was  a signiﬁcant change in gene expression
following vaccination. For IL-8 mRNA, where a temporal trend was
apparent following vaccination, linear regression of mRNA and time
was  used to conﬁrm statistical signiﬁcance.
3. Results
Between February 2008 and October 2009, 100 participants
between the ages of 18 and 60 years were randomly allocated to
receive one of the three vaccines: Rotarix (n = 24), ETEC (n = 21)
or Vivotif (n = 81), or to act as controls who  received no vaccine
(n = 21). Forty-seven of these participants who were available were
subsequently invited to participate on a second occasion, either as
vaccinee or control, at time points separated by intervals of at least
1 year. No vaccinee received the same vaccine twice. Demographic
and clinical characteristics of the participants are shown in Table 2.
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Table  2
Demographic and clinical characteristics of vaccine recipients.
Rotavirus vaccine (n = 24) ETEC vaccine (n = 21) Typhoid vaccine (n = 81) Control (n = 21) P
Sex (M:F) 10:14 11:10 29:52 7:14 0.52
Age  (yrs; median, IQR) 35  (29–41) 42 (35–55) 39 (29–47) 42 (30–50) 0.37
HIV  infected (n, %) 9  (38%) 7 (33%) 39 (48%) 11 (52%) 0.36
BMI  (kg/m2) (median, IQR) 22.3 (19.3–26.9) 21.6 (19–24.6) 23.0 (19.26.3) 20.4 (19.2–24.6) 0.66
CD4  counta (median, IQR) 417 (294–576) 380 (292–402)b 374 (245–545)c 406 (294–541) 0.29
CD4  count ≤ 200 cells/l 0 0 6 1
P values refer to results of statistical testing across all groups.
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The safety of live, attenuated vaccines in HIV infected people
is of paramount importance if vaccines are to play any role in
reducing the burden of common diseases in tropical populations.
In this study we  found that in 34 HIV seropositive adults given
Fig. 1. Changes in IL-8 mRNA expression 1, 2, 4, or 7 days after rotavirus vaccine
administration.  (A) Each point represents the -fold change in mRNA transcript abun-
dance (relative to GAPDH) from the baseline value to the value obtained in the biopsy
taken at that time point. Each individual participant was biopsied twice (baselinea CD4 count expressed as cells/l.
b Data only available for 6 samples.
c Data only available for 38 samples.
ltogether, 34 HIV seropositive adults received 58 courses of live,
ttenuated vaccines orally at one time point or another. Vaccinees
nd controls were well matched for sex, age, body mass index, and
in the HIV seropositives) CD4 count (Table 2).
.1. Clinical adverse events
Diarrhoea  was reported within 7 days of the last dose of vaccine
y 6 participants, all of whom had received 3 doses of Vivotif and
 of whom were HIV seropositive (OR for HIV seropositivity 6.3,
5% CI 0.67–303; P = 0.09). The intervals after which these were
xperienced were 3, 4, 4, 8, 10, and 13 days after the ﬁrst dose.
one of these had diarrhoea which they judged to have been seri-
us enough to seek treatment but two had taken the day off work.
he CD4 counts of those HIV seropositive participants who  experi-
nced diarrhoea within 7 days of last vaccine administration were
in ascending order) 175, 179, 351, 670, and 845 cells/l.
If the period of attribution is extended to 28 days after the ﬁrst
ose of vaccine, 11 episodes of diarrhoea were reported by 10 vac-
inees. Of these, 3 were within 7 days, 5 between 8 and 14 days,
 between 15 and 21 days, and 1 between 22 and 28 days. Of the
0 vaccinees who experienced diarrhoea, 8 were HIV seropositive
Table 3). The two HIV seronegative vaccinees reported diarrhoea
3 days after Vivotif and 21 days after ACAM2017. Including these
ater episodes of diarrhoea changes the Odds Ratio for HIV seropos-
tivity to 5.3 (95% CI 0.98–53; P = 0.04).
Abdominal  pain was reported by 3 vaccine recipients. In two
f these instances, pain occurred during diarrhoeal illnesses, with
nset 4 and 10 days after the ﬁrst doses of Vivotif. One participant
eported pain without diarrhoea 5 days after the ﬁrst dose of Vivotif.
Fever (subjective, not conﬁrmed) was reported by one HIV neg-
tive man  the day after rotavirus vaccination, and by two  HIV
ositive men  13 and 16 days after ETEC vaccination, respectively.
one of these participants sought medical care.
Loss of appetite (scoring 1 on analogue scale of 1–10) was
eported only by one HIV seronegative participant within 24 h
f receiving ACAM2017. Three other HIV positive participants
eported loss of appetite, but all over 3 weeks after the vaccine dose
nd designated not attributable. Only one HIV seronegative partici-
ant reported nausea or vomiting, and that was 12 days after a dose
f Vivotif.
.2. Intestinal cytokine expression
All  recipients of the rotavirus vaccine underwent enteroscopy
or jejunal biopsy collection, but RT-PCR results did not meet quality
tandards for two samples, and one participant did not return on the
cheduled day, so data are available for 21 participants. By RT-qPCR,
RNA of IL-8 showed an immediate down-regulation followed by slow up-regulation which was statistically signiﬁcant (P = 0.02)
n a regression model against time (Fig. 1). There was no dis-
ernible effect of vaccination on IL-1 (Fig. 2) or IFN (Fig. 3). TNF
xpression was undetectable in a considerable number of samples:in  6 cases there was no detectable expression before or after vacci-
nation; in 5 cases mRNA was  detected only before vaccination, and
in 5 cases only after vaccination. In the remaining 5 cases, there
was a modest down-regulation, but this was not statistically sig-
niﬁcant in view of the small number of data pairs. HIV-infected
participants did not differ from HIV-uninfected participants with
respect to changes in cytokine expression following vaccination,
and those biopsies in which TNF expression was  not detectable
were not more likely to come from HIV-infected participants (data
not shown).
4.  Discussionand  at the time point shown) so each point represents all the information obtained
from  one participant. These individual changes are shown in panel (B). The change
over time in IL-8 mRNA shows a statistically signiﬁcant trend (P = 0.02) using lin-
ear regression. Circles represent HIV seronegative individuals and diamonds HIV
seropositive individuals.
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Fig. 2. Changes in IL-1 mRNA expression 1, 2, 4, or 7 days after rotavirus vac-
cine  administration. (A) Each point represents the -fold change in mRNA transcript
abundance  (relative to GAPDH) from the baseline value to the value obtained in
the biopsy taken at that time point. Each individual participant was biopsied twice
(baseline and at the time point shown) so each point represents all the information
obtained  from one participant. These individual changes are shown in panel (B).
a total of 58 courses of three live, attenuated oral vaccines there
was no evidence of serious adverse events: no hospitalisations, no
episodes of diarrhoea requiring treatment, no signiﬁcant febrile
illnesses, and no increase in symptoms such as abdominal pain,
nausea or loss of appetite. There was  no evidence of haematological
toxicity. If we  accept that oral vaccines do not cause diarrhoea after
Fig. 3. Changes in interferon- mRNA expression 1, 2, 4, or 7 days after rotavirus
vaccine  administration. (A) Each point represents the -fold change in mRNA tran-
script abundance (relative to GAPDH) from the baseline value to the value obtained
in  the biopsy taken at that time point. Each individual participant was biopsied twice
(baseline and at the time point shown) so each point represents all the information
obtained  from one participant. These individual changes are shown in panel (B).
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[660 R. Banda et al. / Vacc
 days have elapsed beyond the ﬁnal dose of vaccine, there was no
ncrease in diarrhoea. The interpretation of diarrhoea data in this
etting is difﬁcult if we use HIV seronegative adults as the compar-
son group, as at any given point in time HIV infected adults have a
igher incidence rate of diarrhoeal disease [19]. We  believe that this
xplains the higher diarrhoea incidence after 7 days following vac-
ination. Our data are compatible with the hypothesis that these
accines lead to a modest increase in mild, transient episodes of
iarrhoea beyond 1 week in HIV infected adults. They are also expli-
able with there being a consistently increased risk of diarrhoea in
IV throughout the period of observation.
We found no evidence that vaccines induce intestinal inﬂamma-
ion. IL-8 is a chemokine expressed by epithelial cells on contact
ith potentially invasive bacteria. The other, pro-inﬂammatory,
ytokines showed no change in expression over the week following
accination. While these data do not rule out a pathogenic effect of
hese vaccines, they offer considerable reassurance that rotavirus
accine does not induce inﬂammation. We  are not aware of other
tudies which have examined intestinal tissue following vaccina-
ion against which we can compare our data. Wild-type rotavirus
nfection leads to signiﬁcant mucosal inﬂammation and although
his inﬂammatory response is not fully characterised in humans,
here is evidence that at least interferon- is implicated in the sys-
emic response [20]. In cell culture models using rat and human
ells, TNF, IFN- and IL-6 were induced by rotavirus dsRNA [21].
n animal models, an early IL-8 response is seen [22]. Our data are
urprising in as much as the IL-8 response was delayed, appearing
o rise from an initial down-regulation, for up to 7 days.
The  participants we enrolled were drawn from a community
ohort study where most HIV infected adults have been offered,
nd agree to, monitoring in an HIV treatment programme, and
ake HAART where necessary. Only 6 of our participants had CD4
ounts below 200 cells/l, all of whom had experienced a rapid
rop in CD4 count from their previous clinic visit. Thus we can-
ot be conﬁdent that these vaccines are safe in adults with severe
mmunodeﬁciency (although the bacterial strains are sensitive to
iproﬂoxacin and could be easily treated if symptoms develop). For
ertain infections, parenteral vaccines are available (such as the Vi
olysaccharide vaccine for typhoid) or oral killed vaccines (such
s the killed whole-cell cholera vaccine which has been shown to
e safe in an outbreak in Mozambique [23]). However, oral admin-
stration of live, attenuated vaccines combines the advantage of
ase of administration on a large scale with good immunogenicity,
t least over 2–3 years, and these vaccines remain attractive for
urther development. While our ﬁndings need to be conﬁrmed in
arger studies, they do suggest that safety may  not be an obstacle
o exploiting the potential for oral vaccination in southern Africa,
nd we do not support the view [9] that live oral vaccines should be
ithheld from all HIV-infected adults. However, further studies are
eeded of vaccine safety in severely immunocompromised adults
nd children.
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